熱門詞： 進口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進口電動高溫調(diào)節(jié)閥-德國進口電動高溫法蘭調(diào)節(jié)閥進口電動蒸汽調(diào)節(jié)閥-德國進口電動蒸汽調(diào)節(jié)閥
熱門詞： 進口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進口電動高溫調(diào)節(jié)閥-德國進口電動高溫法蘭調(diào)節(jié)閥進口電動蒸汽調(diào)節(jié)閥-德國進口電動蒸汽調(diào)節(jié)閥
Santarus 美國Santarus
致力于生產(chǎn)消化系統(tǒng)藥物的專業(yè)制藥公司Santarus公司
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on GLUMETZA? (metformin hydrochloride extended release tablets) and CYCLOSET? (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes. The company launched CYCLOSET in November 2010.
Santarus also has a diverse development pipeline with three late-stage product candidates in Phase III clinical programs: budesonide MMX? for induction of remission of active ulcerative colitis, rifamycin SV MMX? for travelers' diarrhea and RHUCIN? (recombinant human C1 inhibitor) for acute attacks of hereditary angioedema. In addition, Santarus plans to initiate a Phase I clinical study in the first half of 2011 with its anti-VLA-1 antibody that the company expects to investigate for the treatment of rheumatoid arthritis.
知識產(chǎn)權(quán)侵權(quán)投訴：不生產(chǎn)任何產(chǎn)品所有產(chǎn)品均來自產(chǎn)品的生產(chǎn)廠商、代理商、經(jīng)銷商，如有侵權(quán)請聯(lián)系：400-006-7520 ，我們會在第一時間處理
本網(wǎng)站所有產(chǎn)品與藥品無關(guān)
滬公網(wǎng)安備31011502016460號
